{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:44Z","timestamp":1791296564993,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.leukres.2012.08.011","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T04:19:14Z","timestamp":1345522754000},"page":"1481-1489","source":"Crossref","is-referenced-by-count":16,"title":["Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture"],"prefix":"10.1016","volume":"36","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.08.011_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.leu.2405054","article-title":"Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic\/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis","volume":"22","author":"Atallah","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0030","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0035","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.leukres.2012.08.011_bib0480","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1309\/AJCPR8GINMBDG9YG","article-title":"Philadelphia chromosome-negative chronic myeloproliferative disease","volume":"132","author":"Thiele","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0050","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1200\/JCO.2009.24.3485","article-title":"Bone marrow fibrosis and diagnosis of essential thrombocythemia","volume":"27","author":"Thiele","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.21543","article-title":"Prodromal myeloproliferative neoplasms: the 2008 WHO classification","volume":"85","author":"Kvasnicka","year":"2010","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.leukres.2012.08.011_bib0485","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0065","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0609.2009.01216.x","article-title":"Karyotype complements the International Prognostic Scoring System for primary myelofibrosis","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","article-title":"Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates","volume":"80","author":"Gangat","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0085","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-009-0745-3","article-title":"Distribution of cytogenetic abnormalities in myelodysplastic syndromes. Philadelphia negative myeloproliferative neoplasms, and the overlap MDS\/MPN category","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0090","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0100","first-page":"277","article-title":"Survival and prognosis among 1,263 patients with polycythemia vera: an international study","volume":"118","author":"Tefferi","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.leukres.2012.08.011_bib0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0110","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0120","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","article-title":"LNK mutations in JAK2 mutation-negative erythrocytosis","volume":"363","author":"Lasho","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0130","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0135","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0140","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0145","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0150","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0155","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0160","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2012.08.011_bib0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0170","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0175","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","article-title":"Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0185","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0190","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.08.011_bib0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.08.011_bib0200","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00277-004-0877-4","article-title":"Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia","volume":"83","author":"Michiels","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0205","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0210","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.21627","article-title":"Is the JAK2(V617F) mutation detectable in healthy volunteers?","volume":"85","author":"Martinaud","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0220","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0225","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0230","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0235","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0240","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kroger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","article-title":"Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow","volume":"22","author":"Larsen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.leukres.2012.08.011_bib0255","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0260","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0265","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0270","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0275","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.08.011_bib0280","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0285","first-page":"1746","article-title":"A prognostic model to predict survival in WHO-defined essential thrombocythemia: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"118","author":"Passamonti","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"10.1016\/j.leukres.2012.08.011_bib0490","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/leu.2011.374","article-title":"Leukemia risk models in primary myelofibrosis: an International Working Group study","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2012.08.011_bib0295","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0300","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet\u2013von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2012.08.011_bib0305","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.leukres.2012.08.011_bib0310","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1538-7836.2009.03686.x","article-title":"Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies","volume":"8","author":"Passamonti","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.leukres.2012.08.011_bib0315","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0320","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.2004.00324.x","article-title":"Pregnancy in essential thrombocythaemia: experience with 40 pregnancies","volume":"73","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0325","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.V99.7.2627","article-title":"Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus","volume":"99","author":"Tefferi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0330","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/leu.2010.269","article-title":"JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2141.1995.tb03306.x","article-title":"Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera","volume":"89","author":"Muller","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0340","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2133.2002.04983.x","article-title":"Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera","volume":"147","author":"Baldo","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0345","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","article-title":"Complications and causes of death in polycythemia vera","volume":"172","author":"Chievitz","year":"1962","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.leukres.2012.08.011_bib0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0355","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs","volume":"89","author":"Crisa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","article-title":"A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)","volume":"52","author":"Finazzi","year":"2004","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.leukres.2012.08.011_bib0365","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0370","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0375","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0385","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0390","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2141.1985.tb02880.x","article-title":"Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre","volume":"61","author":"Messinezy","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0395","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1987.tb06150.x","article-title":"Treatment of primary proliferative polycythaemia by venesection and busulphan","volume":"65","author":"D\u2019Emilio","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0400","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/sj.leu.2404743","article-title":"Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia","volume":"21","author":"Shvidel","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.08.011_bib0405","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0410","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2012.08.011_bib0415","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.leukres.2012.08.011_bib0420","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2012.08.011_bib0425","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMe1115119","article-title":"Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms","volume":"366","author":"Tefferi","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.leukres.2012.08.011_bib0430","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.leukres.2012.08.011_bib0495","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0440","unstructured":"Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia; in press."},{"key":"10.1016\/j.leukres.2012.08.011_bib0445","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0450","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.08.011_bib0455","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.leukres.2012.08.011_bib0500","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood.V118.21.3838.3838","article-title":"SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I\/II study in patients with myelofibrosis","volume":"118","author":"Pardanani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0465","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.08.011_bib0470","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of CYT387, a JAK-1\/2 inhibitor, for the treatment of myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.08.011_bib0475","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T14:54:38Z","timestamp":1714316078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261200344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":95,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S014521261200344X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.08.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}